Sitka Biopharma appoints Sean Cunliffe as Chief Executive

Canadian biotechnology firm is developing a treatment for bladder cancer

Canadian biotech Sitka Biopharma, which is developing a new bladder cancer treatment, has named Sean Cunliffe as Chief Executive.

Sitka is a spin-off from CDRD Ventures (CVI), the commercialisation arm of the Centre for Drug Research and Development (CDRD) and the University of British Columbia (UBC).

Cunliffe has more than 30 years of pharmaceutical marketing and sales experience across a variety of therapeutic areas. Most recently, he has held senior roles at Angiotech Pharmaceutical and Neuromed Pharmaceuticals, which is now Zalicus Inc.

He has also held several leadership roles at Wyeth Pharmaceuticals, including Vice President of New Product Marketing where he co-chaired, along with Discovery, the Neuroscience and Cardiovascular leadership teams, Vice President Marketing and Global Business Manager of Neuroscience and Vice President of Cardiovascular and Gastrointestinal Marketing.

Prior to Wyeth, Cunliffe was Group Director US Marketing, Gastrointestinal and Anti-Viral Products at Glaxo Wellcome. He also held sales and marketing roles in Canada with Glaxo and Astra Pharmaceuticals before moving to the US to work in both global and US domestic commercial functions.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Subscribe now